GET DAILY SIGNALSRecursion Pharmaceuticals (RXRX) and the Path to a +96% Move Toward $7.50
Key Takeaways
- The central target of $7.50 is the arithmetic mean of four verified analyst price targets, rounded from roughly $7.48.
- At a latest price near $3.83, reaching $7.50 would require about 96% upside, a very large move.
- The analyst target range is wide, from $5.90 (Morgan Stanley) to $10.00 (JPMorgan), reflecting sharply different views on the pipeline.
- Supporting factors include positive REC-4881 clinical data, high-value pharma partnerships, and an extended cash runway.
- Principal risks are continued net losses, shareholder dilution from a $200 million follow-on offering, and binary clinical outcomes.
- Investors should monitor upcoming data readouts, partnership milestones, and cash-burn trends over the next 12 months.
Analyst Price Targets and Consensus View
Recursion Pharmaceuticals, Inc. (RXRX) is a clinical-stage biotechnology company that applies artificial intelligence and automation to industrialize drug discovery. Four current, individually attributed analyst targets were reviewed: JPMorgan at $10.00 (Buy), Needham at $8.00 (Buy), Bank of America Securities at $6.00 (Hold), and Morgan Stanley at $5.90 (Equal-Weight). The arithmetic mean of these four figures is approximately $7.48, rounded to a central target of $7.50.
The range of $5.90 to $10.00 is unusually wide, illustrating genuine disagreement about the value of Recursion's early-stage pipeline. The bullish view, expressed by JPMorgan, centers on the blockbuster potential of REC-4881 in familial adenomatous polyposis (FAP), a hereditary condition, with estimated U.S. peak sales exceeding $1 billion and a roughly 60% probability of success. More cautious firms, such as Morgan Stanley and Bank of America, weigh the company's sustained operating losses, the early stage of most clinical programs, and recent share dilution against that optionality. In late 2026, JPMorgan lowered its target from $11 to $10, while Morgan Stanley raised its target from $5.30 to $5.90, reflecting modest, incremental revisions rather than a wholesale shift in sentiment. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
Shares traded near $3.83 in early November 2026, with a market capitalization of roughly $2.3 billion and a 52-week range spanning from about $2.77 to $5.76. Reaching the $7.50 central target would require a gain of approximately 96% from current levels, which is best characterized as a very large move for a single holding period.
Any path toward that figure would likely depend on translating clinical momentum into de-risked, late-stage assets. Recursion reported third-quarter 2026 results with revenue of $18.55 million, comfortably above consensus estimates of about $14.81 million, and an adjusted loss per share of $0.22. The company has also extended its cash runway into 2028 and continues to generate milestone revenue from partners including Sanofi and Genentech. Those are supportive signals, but they do not by themselves justify a near-doubling; the central target implicitly assumes successful clinical execution that is not yet proven.
What Could Support a Move Toward the Target
- Positive Phase 2 data for REC-4881 in FAP presented in late 2026 showed deep and durable polyp burden reductions, strengthening the case for its commercial potential.
- Partnership economics: Sanofi exercised an option on a potential first-in-class immunology candidate, triggering a milestone payment, and cumulative partnership inflows have exceeded $500 million.
- An extended cash runway through early 2028 reduces near-term financing risk and gives the pipeline time to mature.
- Strategic validation from technology partners, including Nvidia, and continued accumulation by funds such as ARK Invest highlight institutional interest in AI-driven drug discovery.
What Could Prevent the Target From Being Reached
- The company remains deeply unprofitable, with adjusted losses per share still negative and no approved commercial products yet generating recurring revenue.
- A $200 million follow-on offering priced at $3.25 in October 2026 added significant share count, pressuring per-share value.
- Clinical-stage biotech carries binary risk: a single disappointing trial readout could materially reset the valuation.
- Analyst disagreement is wide, and the most cautious targets sit well below the $7.50 average, underscoring uncertainty about execution and market adoption.
Technical Levels and Market Structure
From a technical standpoint, the $3.25 follow-on offering price and the 52-week low near $2.77 form a lower support zone, while the recent trading high around $4.17 and the 52-week high near $5.76 represent overhead resistance. The psychological $5.00 level sits between the current price and the central target, and a decisive move above it would be a notable change in market structure. The $7.50 target implies a breakout well beyond the stock's established trading range.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a research horizon of approximately 12 months, though individual firms may differ in their assumptions. Investors should watch upcoming REC-4881 and REC-1245 data updates, any additional partnership or milestone announcements, quarterly cash-burn trends, and any further changes to analyst targets or ratings. Regulatory and financing developments, including the possibility of additional equity raises, are also material. From what I see, this is important because the binary nature of clinical readouts can shift sentiment quickly.
Final Assessment
The question of whether RXRX can reach $7.50 ultimately hinges on clinical and commercial execution rather than near-term trading dynamics. The central target, derived from four verified analyst price targets, implies roughly 96% upside from a price near $3.83. The strongest supports are encouraging REC-4881 data, lucrative partnerships, and a lengthened cash runway, while the principal obstacles are continued losses, dilution, and the binary nature of biotech development. With analyst targets spanning $5.90 to $10.00, the market itself has not reached a consensus on the company's value. No outcome is guaranteed, and the target should be viewed as a reference point for debate rather than a forecast.
Exploring AI-Driven Signals for Stocks Like RXRX
One tool I find useful in my own process is Tickeron’s AI Daily Buy/Sell Signals. It applies artificial intelligence to monitor thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on technical behavior and market conditions. I check it periodically to get a systematic view alongside traditional analysis and to spot potential shifts in momentum for names like this one.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.
RXRX saw its Stochastic Oscillator leaves the overbought zone
The Stochastic Oscillator for RXRX moved out of overbought territory on November 02, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 57 similar instances where the indicator exited the overbought zone. In 55 of the 57 cases the stock moved lower. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for RXRX moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In 24 of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RXRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
RXRX broke above its upper Bollinger Band on October 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on RXRX as a result. In 83 of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.
The Moving Average Convergence Divergence (MACD) for RXRX just turned positive on October 28, 2026. Looking at past instances where RXRX's MACD turned positive, the stock continued to rise in 41 of 51 cases over the following month. The odds of a continued upward trend are 80%.
RXRX moved above its 50-day moving average on October 23, 2026 date and that indicates a change from a downward trend to an upward trend.
The 50-day moving average for RXRX moved above the 200-day moving average on October 12, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +14.47% 3-day Advance, the price is estimated to grow further. Considering data from situations where RXRX advanced for three days, in 207 of 248 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
The Aroon Indicator entered an Uptrend today. In 116 of 131 cases where RXRX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 89%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 35 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.245) is normal, around the industry mean (3.104). P/E Ratio (-3.830) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (30.030) is also within normal values, averaging (439.647).
The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. RXRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 81 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RXRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement